PUMA BIOTECHNOLOGY INC
PBYINASDAQTrading Snapshot
- Day Range
- $9.69 – $9.94
- 52-Week Range
- $4.58 – $9.98
- Volume
- $6.10B
- Avg Volume
- $6.92B
- Shares Outstanding
- 50.9M
- Next Earnings
- Nov 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $228M
- Last Q Revenue
- $57M
- P/E Ratio
- 18.3
- P/S Ratio
- 2.2x
- EPS (TTM)
- $0.52
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.3%
Why Investors Own PBYI
- ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PUMA BIOTECHNOLOGY INC
PBYI
StockOtter · stockotter.spaceAbout PUMA BIOTECHNOLOGY INC
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI)
Puma Biotechnology (NASDAQ: PBYI - Get Free Report) and TG Therapeutics (NASDAQ: TGTX - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on th
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I b
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).